Interleukin-10 G-1082A and C-819T Polymorphisms as Possible Molecular Markers of Urothelial Bladder Cancer

Archives of Medical Research

Volumn 40, Issue 2, 2009, Pages 97-102

  Ahirwar, Dinesh ^a   Mandhani, Anil ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Haplotypes; Interleukin; Single nucleotide polymorphism; Urothelial bladder cancer

Indexed keywords

MOLECULAR MARKER;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; INTERLEUKIN 10 GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SMOKING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 60349104574     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.11.006     Document Type: Article

References (36)

1. Sinha R., Anderson D.E., McDonald S.S., and Greenwald P. Cancer risk and diet in India. J Postgrad Med 49 (2003) 222-228
2. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacilli Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325 (1991) 1205-1209
3. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176 (2006) 2414-2422
4. Stern M.C., Umbach D.M., van Gils C.H., Lunn R.M., and Taylor J.A. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 10 (2001) 125-131
5. Moore K.W., de Waal Malefyt R., Coffman R.L., and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
6. Sato T., McCue P., Masuoka K., et al. Interleukin 10 production by human melanoma. Clin Cancer Res 2 (1996) 1383-1390
7. Yang A.S., and Lattime E.C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 63 (2003) 2150-2157
8. Levy Y., and Brouet J.C. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93 (1994) 424-428
9. Westendorp R.G., Langermans J.A., Huizinga, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349 (1997) 170-173
10. Reuss E., Fimmers R., Kruger A., Becker C., Rittner C., and Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immunity 3 (2002) 407-413
11. Suárez A., Castro P., Alonso R., Mozo L., and Gutiérrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75 (2003) 711-717
12. Chatterjee R., Batra J., Kumar A., et al. Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clin Exp Allergy 35 (2005) 914-919
13. McCarron S.L., Edwards S., Evans P.R., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62 (2002) 3369-3372
14. Havranek E., Howell W.M., Fussell H.M., Whelan J.A., Whelan M.A., and Pandha H.S. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 173 (2005) 709-712
15. Lech-Maranda E., Baseggio L., Bienvenu J., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103 (2004) 3529-3534
16. Ahirwar D., Kesarwani P., Manchanda P.K., Mandhani A., and Mittal R.D. Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184 (2008) 1-8
17. Mittal R.D., Singh R., Manchanda P.K., Ahirwar D., Kesarwani P., and Gangwar R. XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy. Cancer Biol Ther 7 (2008) 645-650
18. th ed. Q12 (1997), Wiley-Liss, New York
19. Mostofi F.K., Sobin L., and Torloni H. histological typing of urothelial bladder tumors. International histological classification of tumor. No. 10 (1973), World Health Organization, Geneva pp. 15-34
20. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
21. Perrey C., Turner S.J., Pravica V., Howell W.M., and Hutchinson I.V. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 7 (1999) 127-128
22. Excoffier L., and Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 12 (1995) 921-927
23. Millan-Rodriquez F., Chechile-Tomiolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
24. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
25. Moore K.W., de Waal Malefyt R., and Coffman R.L. O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19 (2001) 683-765
26. Berg D.J., Davidson N., Kühn R., et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Investig 98 (1996) 1010-1020
27. Kundu N., and Fulton A.M. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 180 (1997) 55-61
28. Giordani L., Bruzzi P., Lasalandra C., et al. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49 (2003) 1664-1667
29. Alas S., Emmanouilides C., and Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7 (2001) 709-723
30. Mocellin S., Marincola F.M., and Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78 (2005) 1043-1051
31. García-Hernández M.L., Hernández-Pando R., Gariglio P., and Berumen J. Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105 (2002) 231-243
32. Cai T., Mazzoli S., Meacci F., et al. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma. J Urol 178 (2007) 1906-1912
33. Basturk B., Yavascaoglu I., Oral B., Göral G., and Oktay B. Cytokine gene polymorphisms can alter the effect of Bacillus Calmette-Guérin (BCG) immunotherapy. Cytokine 35 (2006) 1-5
34. Guo W., Wang N., Wang Y.M., et al. Interleukin-10 -1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China. World J Gastroenterol 11 (2005) 858-862
35. Jin-Guang Y., Lin-Bo G., Yun-Guang L., Jun L., and Guang-Fu P. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 388 (2008) 84-88
36. Vassallo R., Tamada K., Lau J.S., Kroening P.R., and Lieping Chen L. Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. J Immunol 175 (2005) 2684-2691